Aquestive Therapeutics, Inc.

NASDAQ:AQST

4.95 (USD) • At close September 18, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

20232022202120202019201820172016
Revenue 50.58347.6850.83245.84952.60967.4366.91851.785
Cost of Revenue 20.61519.38614.98912.96420.36120.98819.8216.378
Gross Profit 29.96828.29435.84332.88532.24846.44247.09835.407
Gross Profit Ratio 0.5920.5930.7050.7170.6130.6890.7040.684
Reseach & Development Expenses 13.10417.48117.04719.88620.57423.11222.13315.45
General & Administrative Expenses 0000072.26425.07820.804
Selling & Marketing Expenses 00000000
SG&A 31.7552.87953.47555.89264.34272.26425.07820.804
Other Expenses 00000-0.0050-0.099
Operating Expenses 44.85470.3670.52275.77884.91695.37647.21136.254
Operating Income -14.886-42.066-34.679-42.893-52.668-48.934-0.113-0.847
Operating Income Ratio -0.294-0.882-0.682-0.936-1.001-0.726-0.002-0.016
Total Other Income Expenses Net 7.261-12.344-35.86-12.89-13.578-5.283-1.123-2.612
Income Before Tax -7.625-54.41-70.539-55.783-66.246-61.376-8.943-9.602
Income Before Tax Ratio -0.151-1.141-1.388-1.217-1.259-0.91-0.134-0.185
Income Tax Expense 0.2455.79219.4979.5796.413-4.7317.7076.044
Net Income -7.87-60.202-90.036-65.362-72.659-61.376-8.943-9.602
Net Income Ratio -0.156-1.263-1.771-1.426-1.381-0.91-0.134-0.185
EPS -0.13-1.24-2.36-1.94-2.87-2.96-0.45-0.39
EPS Diluted -0.13-1.24-2.36-1.94-2.87-2.96-0.45-0.39
EBITDA -13.541-41.967-34.256-42.761-52.032-48.3873.6882.945
EBITDA Ratio -0.268-0.88-0.674-0.933-0.989-0.7180.0550.057